

### DAFTAR PUSTAKA

1. Angelova P, Boyadjiev N. a Review on the Models of Obesity and Metabolic Syndrome in Rats. *Trakia J Sci.* 2013;11(1):5–12.
2. Djausal AN. EFFECT OF CENTRAL OBESITY AS RISK FACTOR OF METABOLIK SYNDROME. *J Majority.* Vol 4 No 3. 2015
3. Srikanthan K, Feyh A, Visweshwar H, Shapiro JJ, Sodhi K. Systematic review of metabolic syndrome biomarkers: A panel for early detection, management, and risk stratification in the West Virginian population. *Int J Med Sci.* 2016;13(1):25–38.
4. Zwaka T, Hombach V, Torzewski J. C-Reactive Protein–Mediated Low Density Lipoprotein Uptake by Macrophages. *Circulation* .2009;103(9):1194–7.
5. Meddy S. *Nutrisi Kedelai Pada Obesitas Dan Metabolik Sindrom.* 2010.
6. Kusoy, K. PREVALENSI OBESITAS PADA REMAJA DI KABUPATEN MINAHASA. *JURNAL e-Biomedik;* 2013
7. OktoMalioputri. Pengaruh Lama Pemberian Diet Tinggi Kolesterol Terhadap KadarLDL, TGF- $\beta$  DAN IL-17 Pada Serum Tikus Putih (*Rattus Novergius*) Strain Wistar. Universitas Andalas.2016
8. Wisnu Wardhana. The effect of soybean (*Glycine max* (L.) Merr.) stewed water on kidney TNF- $\alpha$  expressions and liver protein profiles of renal fibrosis rats (*Rattus norvegicus*) induced with Streptokinase. Universitas Brawijaya, 2015.
9. Demonty I, Lamarche B, Deshaies Y, Jacques H. Role of soy isoflavones in the hypotriglyceridemic effect of soy protein in the rat. *J Nutr Biochem.* 2012;13(11):671–7.
10. Ika. Pengaruh Pemberian Ekstrak Kacang Hijau Terhadap Kadar Kolesterol Total Pada Wanita Hiperkolestolemia. Semarang. UNDIP, 2015;1–32.
11. Jensen L. The Effects of Soy Isoflavones on Obesity. 2014;(October).
12. Wahba IM, Mak RH. Obesity and Obesity-Initiated Metabolic Syndrome : Mechanistic Links to Chronic Kidney Disease. 2010;550–62.

13. Putu Filla J.F. Hs-CRP As Biomarker Of Coronary Heart Disease. University of Lampung, 2015;4:75–9.
14. Maulana R, Hidayaturrahmi H, Wahyuniati N, Aceh B. Peran Sistem Komplemen pada Patogenesis Aterosklerosis. 2015;(October).
15. Aterosklerosis MDAN. Makrofag dan aterosklerosis. 2017;5(7):61–7.
16. Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko A V, Orekhov AN. Mechanisms of foam cell formation in atherosclerosis. 2017
17. Caveats P. Isoflavones: Anti-Inflammatory Benefit and Possible Caveats. 2016;(Table 1):1–16.
18. Design D. Genistein suppresses tumor necrosis factor  $\alpha$  -induced inflammation via modulating reactive oxygen species / Akt / nuclear factor  $\kappa$  B and adenosine monophosphate-activated protein kinase signal pathways in human synoviocyte MH7A cells. 2014;315–23.
19. Kurniawati, D. M., Dharmana, E., Rachmawati, B., Gde, T. & Pemayun, D. Pengaruh pemberian ekstrak kedelai hitam ( Glycine soja .) berbagai dosis terhadap kadar glukosa darah , kadar insulin , dan HOMA-IR. **6**, (2017).
20. Nurhalida, Q. & Rahayu Lestari, S. PENGARUH NATTO KEDELAI HITAM (Glycine soja L) TERHADAP JUMLAH FOAM CELL DAN KETEBALAN DINDING AORTA MENCIT MODEL ATEROSKLEROSIS. 1–6. (2015).
21. Ayuningtyas,R . *Pengaruh pemberian tempe terhadap memori spasial tikus wistar terinduksi diabetes*. (2016).
22. Leny, C. *et al*. Pengaruh Pemberian Genistein Terhadap Penurunan Kadar Tnf Alpha. **X**, (2018).
23. Suryarahman, Stevenya. GENISTEIN TOPIKAL MENURUNKAN EKSPRESI TNF-  $\alpha$  PADA KORNEA MATA TIKUS (RATTUS NOVERGICUS STRAIN WISTAR) MODEL INFLAMASI.. (2015).
24. Zhang H, Park Y, Wu J, Chen X, Lee S, Yang J, et al. Role of TNF-  $\alpha$  in vascular dysfunction. 2009;230:219–30.
25. Kwon YW, Heo SC, Jeong GO, Yoon JW, Mo WM, Lee MJ, et al. Tumor necrosis factor- $\alpha$ -activated mesenchymal stem cells promote endothelial progenitor cell homing and angiogenesis. *Biochim Biophys Acta - Mol Basis Dis*. 2013;1832(12):2136–44.

26. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. *Arch Gen Psychiatry*. 2013;70(1):31–41.
27. Illán-Gómez F, González-Ortega M, Orea-Soler I, Alcaraz-Tafalla MS, Aragón-Alonso A, Pascual-Díaz M, et al. Obesity and inflammation: Change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. *Obes Surg*. 2012;22(6):950–5.
28. Black S, Kushner I, Samols D. C-reactive protein. *J Biol Chem*. 2010;279(47):48487–90.
29. Ridker PM. C-Reactive Protein: A Simple Test to Help Predict Risk of Heart Attack and Stroke. *Circulation*. 2013;108(12):81e–85. 7
30. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. *Front Immunol*. 2018;9(APR):1–11.
31. Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: A systematic review and meta-analysis. *Obes Rev*. 2013;14(3):232–44.
32. Singh SK, Suresh M V., Voleti B, Agrawal A. The connection between C-reactive protein and atherosclerosis. *Ann Med*. 2009;40(2):110–20.
33. Hayashino Y, Jackson JL, Hirata T, Fukumori N, Nakamura F, Fukuhara S, et al. Effects of exercise on C-reactive protein, inflammatory cytokine and adipokine in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. *Metabolism*. 2014;63(3):431–40.
34. Labarrere CA, Zaloga GP. C-reactive protein: From innocent bystander to pivotal mediator of atherosclerosis. *Am J Med*. 2009;117(7):499–507.
35. Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. *Clin Chim Acta*. 2013;424:245–52.
36. Shashkin P, Dragulev B, Ley K. Macrophage Differentiation to Foam Cells. *Curr Pharm Des*. 2011;11(23):3061–72. 32. Kruth HS, Huang W, Ph D, Ishii I, Ph D. Macrophage Foam Cell Formation with Native LDL. 2012.
37. Charney LH, Vascular RB. Macrophages in atherosclerosis: a dynamic balance. 2015;13(10):709–21.

38. Eckel RH, Alberti KGMM, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet* (London, England). 2010;375(9710):181–3.
39. Ghezzi AC, Cambri LT, Botezelli JD, Ribeiro C, Dalia RA, De Mello MAR. Metabolic syndrome markers in wistar rats of different ages. *Diabetol Metab Syndr*. 2012;4(1):1–7.
40. Achike FI, To NHP, Wang H, Kwan CY. Obesity, metabolic syndrome, adipocytes and vascular function: A holistic viewpoint. *Clin Exp Pharmacol Physiol*. 2011;38(1):1–10.
41. Bruce KD, Hanson MA. The Developmental Origins, Mechanisms, and Implications of Metabolic Syndrome. *J Nutr*. 2010;140(3):648–52.
42. Dupas J, Feray A, Goanvec C, Guernec A, Samson N, Bougaran P, et al. Metabolic Syndrome and Hypertension Resulting from Fructose Enriched Diet in Wistar Rats. *Biomed Res Int*. 2017.
43. Simmons RK, Alberti KGMM, Gale EAM, Colagiuri S, Tuomilehto J, Qiao Q, et al. The metabolic syndrome: Useful concept or clinical tool? Report of a WHO expert consultation. *Diabetologia*. 2010;53(4):600–5.
44. Moy FM, Bulgiba A. The modified NCEP ATP III criteria maybe better than the IDF criteria in diagnosing Metabolic Syndrome among Malays in Kuala Lumpur. *BMC Public Health*. 2010;10:2–7.
45. Sutin AR, Costa PT, Uda M, Ferrucci L, Schlessinger D, Terracciano A. Personality and metabolic syndrome. *Age* (Omaha). 2010;32(4):513–9.
46. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: Underlying causes and modification by exercise training. *Compr Physiol*. 2013;3(1):1–58.
47. Guo S. Insulin signaling, resistance, and metabolic syndrome: Insights from mouse models into disease mechanisms. *J Endocrinol*. 2014;220(2).
48. Shah R V., Murthy VL, Abbasi SA, Blankstein R, Kwong RY, Goldfine AB, et al. Visceral adiposity and the risk of metabolic syndrome across body mass index: The MESA study. *JACC Cardiovasc Imaging*. 2014;7(12):1221–35.
49. McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. *Clin Dermatol*. 2018;36(1):14–20.
50. Bonomini F, Rodella LF, Rezzani R. Metabolic Syndrome, Aging and Involvement of Oxidative Stress. *Aging Dis*. 2015;6(2):109.

51. Li G, Scull C, Ozcan L, Tabas I. NADPH oxidase links endoplasmic reticulum stress, oxidative stress, and PKR activation to induce apoptosis. *J Cell Biol.* 2010;191(6):1113–25.
52. Sturm A. Authentisch in der Grauzone. *Horizont.* 2017;21(9):1–3.
53. Kaila B, Raman M. Obesity: A review of pathogenesis and management strategies. *Can J Gastroenterol.* 2009;22(1):61–8.
54. Coutinho T, Goel K, Corrêa De Sá D, Carter RE, Hodge DO, Kragelund C, et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: Role of “normal weight central obesity.” *J Am Coll Cardiol.* 2013;61(5):553–60.
55. Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, Sawai T, et al. The role of TNF- $\alpha$  in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): A study using a human RA/SCID mouse chimera. *Rheumatology.* 2012;41(3):329–37.
56. Moller DE, Kaufman KD. Metabolic Syndrome: A Clinical and Molecular Perspective. *Annu Rev Med.* 2009;56(1):45–62.
57. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the Metabolic Syndrome in the United States, -012. *Jama.* 2015;313(19):1973.
58. Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: Pathophysiology and Management. *J Am Coll Cardiol.* 2018;71(1):69–84.
59. Krüger K. Inflammation during Obesity – Pathophysiological Concepts and Effects of Physical Activity. *Dtsch Z Sportmed.* 2017;2017(7–8):163–9. 56. Lusic AJ. NIH Public Access. *Nature.* 2010;407(6801):233–41.
60. Wu MY, Li CJ, Hou MF, Chu PY. New insights into the role of inflammation in the pathogenesis of atherosclerosis. *Int J Mol Sci.* 2017;18(10).
61. Momiyama Y, Adachi H, Fairweather D, Ishizaka N, Saita E. Inflammation, Atherosclerosis and Coronary Artery Disease. *Clin Med Insights Cardiol.* 2014;8s3:CMC.S39423.
62. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ. Nitric oxide and atherosclerosis: An update. *Nitric Oxide - Biol Chem.* 2011;15(4):265–79.
63. Tomkin G.H., and Owens D. LDL as a cause of atherosclerosis. *Atheroscler*

Thromb J Atheroscler Thromb. 2012;5(1):13–21.

64. Huo Y, Zhao L, Hyman MC, Shashkin P, Harry BL, Burcin T, et al. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. *Circulation*. 2011;110(14):2024–31.
65. Kruth HS, Huang W, Ishii I, Zhang WY. Macrophage foam cell formation with native low density lipoprotein. *J Biol Chem*. 2012;277(37):34573–80.
66. Fishbein MC, Fishbein GA. Arteriosclerosis: Facts and fancy. *Cardiovasc Pathol*. 2015;24(6):335–42.
67. Costopoulos C, Huang Y, Brown AJ, Calvert PA, Hoole SP, West NEJ, et al. Plaque Rupture in Coronary Atherosclerosis Is Associated With Increased Plaque Structural Stress. *JACC Cardiovasc Imaging*. 2017;10(12):1472–83.
68. Phipps RP. Atherosclerosis: The emerging role of inflammation and the CD40-CD40 ligand system. *Proc Natl Acad Sci [Internet]*. 2011;97(13):6930–2.
69. Insull W. The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment. *Am J Med*. 2009;122(1 SUPPL.):S3–14.
70. Pilsková L, Riečanský I, Jagla F. The physiological actions of isoflavone phytoestrogens. *Physiol Res*. 2010;59(5):651–64.
71. Borrás C, Gambini J, Gómez-Cabrera MC, Sastre J, Pallardó F V., Mann GE, et al. Genistein, a soy isoflavone, up-regulates expression of antioxidant genes: involvement of estrogen receptors, ERK1/2, and NFkappaB. *FASEB J*. 2011;20(12):2136–8.
72. Kim H, Peterson TG, Barnes S. Mechanisms of action of the soy isoflavone genistein: Emerging role for its effects via transforming growth factor  $\beta$  signaling pathways. *Am J Clin Nutr*. 2011;68(6 SUPPL.):1418–25.
73. Hall WL, Vafeiadou K, Hallund J, Bu S, Ferrari M, Branca F, et al. Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women : interactions with genotype and equol production 1 X 3. 2015;1260–8.
74. Campos MDGR, Matos MP. Bioactivity of isoflavones: Assessment through a theoretical model as a way to obtain a “Theoretical Efficacy Related to Estradiol (TERE).” *Int J Mol Sci*. 2010;11(2):480–91.
75. Miller KA, Frankel F, Takahashr H, Vance N, Stiegerwald C, Edelstein S. Collected literature on isoflavones and chronic diseases. *Cogent Food Agric*.

2016;2(1):1–12.

76. Mujić I, Šertović E, Jokić S, Sarić Z, Alibabić V, Vidović S, et al. Isoflavone content and antioxidant properties of soybean seeds. *Croat J Food Sci Technol.* 2011;3(1):16–20.
77. Panneerselvam S, Packirisamy RM, Bobby Z, Sridhar MG. *Biochemistry & Analytical Biochemistry* Protective Effect of Soy Isoflavones ( from Glycine max ) on Adipose Tissue Oxidative Stress and Inflammatory Response in an Experimental Model of Post-menopausal Obesity: The Molecular Mechanisms. 2016;5(2).
78. Mishra N, Mishra VN, Devanshi. Natural phytoestrogens in health and diseases. *Journal, Indian Acad Clin Med.* 2011;12(3):205–11.
79. Yoon GA, Park S. Antioxidant action of soy isoflavones on oxidative stress and antioxidant enzyme activities in exercised rats. *Nutr Res Pract.* 2014;8(6):618–24.
80. Messina S, Bitto A, Aguenouz M, Vita GL, Polito F, Irrera N, et al. The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF- $\alpha$  activation and ameliorates muscle function and morphology in mdx mice. *Neuromuscul Disord.* 2011;21(8):579–89.
81. Turner R, Baron T, Wolfram S, Minihane AM, Cassidy A, Rimbach G, et al. Effect of circulating forms of soy isoflavones on the oxidation of low density lipoprotein. *Free Radic Res.* 2011;38(2):209–16.
82. Cena ER, Steinberg FM. Soy may help protect against cardiovascular disease. *Calif Agric.* 2011;65(3):118–23.
83. Lazarov S. New risk factors for atherosclerosis. *Gen Med.* 2010;4(4):26–34.
84. Sudigo Sastroasmoro. *Dasar-dasar Metodologi Penelitian Klinis.* (CV Sagung seto,2011).
85. Sartini, S., Djide, M.N., Permana, A. D & Ismail,I. Ekstraksi Isoflavon Kedelai dan Penentu Kadarnya Secara Ultra Fast Liquid Chromotography (UFCL). *J.Sainsmat III.* 130-134 (2014)
86. Leny C, Prodi W, A, Wallis K, et al. Pengaruh Pemberian Genistein Terhadap Penurunan Kadar Tnf Alpha. 2018;X(I).
87. Irene Nucifear. Pengaruh Pemberian Sari Ubi Ungu (Ipomea Batatas L.) Terhadap Kadar High Sensitivity C-Reactive Protein (Hs-CRP) Pada Tikus Sparague Dawley Dengan Tinggi Lemak. Semarang. FK UNDIP,2018

88. Nurhalida Q, Rahayu Lestari S. Pengaruh Natto Kedelai Hitam (Glycine Soja L) Terhadap Jumlah Foam Cell Dan Ketebalan Dinding Aorta Mencit Model Aterosklerosis. 2015 :1–6.
89. Dahlan M. Statistik Untuk Kedokteran dan Kesehatan. Jakarta : Salemba Medika : 2011
90. Nishimura S, Manabe I, Nagasaki M, Eto K. CD8+effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. *Nat. Med.* 2011. 15(2), 914–920.
91. Castro SB, Junior CO, Souza A.C, Dias AT, Juliano MA, Castañon MC, Almeida MV, Teixeira HC and Ferre ira A .2013. Genistein derivatives down-modulates pro-inflammatory cytokines in activated J774A.1 cells and reverses clinical signs of experimental autoimmune encephalomyelitis. doi: 10:3389
92. Chen et al. 2015. Association between C-reactive protein, incident liver cancer and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study. *Cancer Epidemiol Biomarkers Prev*; 24(2): 386–392. doi: 10.1158/1055-9965
93. Lusis, A. J. Atherosclerosis. *Nature*, Vol 407. (2015)
94. Chabbra, N. 2011. Endothelial Dysfunction – A Predictor of Atherosclerosis. *Internet Journal of Medical Update*, 4 (1) : 33-41
95. Astuti, P. 2014. Fermentasi Kedelai Hitam Detam 2 oleh *Bacillus subtilis* natto untuk Meningkatkan Kandungan Isoflavon Aglikon. Skripsi. Bogor : IPB
96. Grassi, D., Dessideri, G. & Ferri, C. 2010. Flavonoids: Antioxidants Against Atherosclerosis. *Nutrients*, 2 : 889-902
97. Pan, H. C., Yang, D. Y., Ho, S. P., Sheu, M. L., Chen, C. J., Hwang, S. M., Chang, M. H. & Cheng, F. C. 2011. Escalated Regeneration in Sciatic Nerve Crush Injury by The Combined Therapy of Human Amniotic Fluid Mesenchymal Stem Cells and Fermented Soybean Extracts, Natto. *Journal of Biomedical Science*, 16 (75):1-12